Results 11 to 20 of about 30,877 (270)

The possibilities of using beta-blocker bisoprolol in patients with stable angina with concomitant bronchial asthma.

Kardiologiia, 2022
Aim    To compare efficacy and safety of treatments with the calcium antagonist (CA) verapamil, the cardioselective β-blocker (BB) bisoprolol, and a combination therapy with bisoprolol and amlodipine in patients with stable angina (SA) with concurrent ...
N. Grigorieva, T. Ilushina, K. Kolosova
semanticscholar   +2 more sources

EFFICACY AND SAFETY OF IVABRADINE AND BISOPROLOL IN PATIENTS WITH ISCHEMIC HEART DISEASE: RESULTS OF COMPARATIVE RANDOMIZED OPEN STUDY

Рациональная фармакотерапия в кардиологии, 2016
Aim. To study influence of ivabradine as compared with bisoprolol on clinical and hemodynamic indices, exercise tolerance, endothelial function, quality of life (QL) and erectile function in patients with ischemic heart disease. Material and methods.
R. D. Kurbanov, A. O. Kan, F. M. Bekmetova, A. B. Shek   +3 more
doaj   +2 more sources

Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)

Trials, 2022
Background Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity, mortality and healthcare costs. Beta blockers are well-established drugs widely used to treat cardiovascular conditions.
Seonaidh Cotton, Graham Devereux, Hassan Abbas, Andrew Briggs, Karen Campbell, Rekha Chaudhuri, Gourab Choudhury, Dana Dawson, Anthony De Soyza, Shona Fielding, Simon Gompertz, John Haughney, Chim C. Lang, Amanda J. Lee, Graeme MacLennan, William MacNee, Kirsty McCormack, Nicola McMeekin, Nicholas L. Mills, Alyn Morice, John Norrie, Mark C. Petrie, David Price, Philip Short, Jorgen Vestbo, Paul Walker, Jadwiga Wedzicha, Andrew Wilson, Brian J. Lipworth   +28 more
doaj   +2 more sources

Application of physiologically based biopharmaceutics modeling to understand the impact of dissolution differences on in vivo performance of immediate release products: The case of bisoprolol

CPT: Pharmacometrics & Systems Pharmacology, 2021
Merck KGaA observed slight differences in the dissolution of Concor® (bisoprolol) batches over the years. The purpose of this work was to assess the impact of in vitro dissolution on the simulated pharmacokinetics of bisoprolol using in vitro–in vivo ...
Joyce S. Macwan, Grace Fraczkiewicz, Mauro Bertolino, Phillip Krüger, Sheila‐Annie Peters   +4 more
doaj   +2 more sources

Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol

Pharmacogenomics and Personalized Medicine, 2022
Vanessa Fontana,1,2 Richard Myles Turner,1,2 Ben Francis,3 Peng Yin,3 Benno Pütz,4 Timo P Hiltunen,5 Sanni Ruotsalainen,6 Kimmo K Kontula,5 Bertam Müller-Myhsok,1,4 Munir Pirmohamed1,2,7 1The Wolfson Centre for Personalised Medicine, Institute of ...
Fontana V, Turner RM, Francis B, Yin P, Pütz B, Hiltunen TP, Ruotsalainen S, Kontula KK, Müller-Myhsok B, Pirmohamed M   +9 more
doaj   +2 more sources

Novel potentiometric methods for the estimation of bisoprolol and alverine in pharmaceutical forms and human serum

Reviews in Analytical Chemistry, 2021
Two new potentiometric sensors were created for the quantification of bisoprolol fumarate and alverine citrate in bulk pharmaceutical dosage forms and human serum.
Elgendy Khaled, Elmosallamy Mohamed A.F., Soltan Moustafa K., Amin Alaa S., Elshaprawy Dina S.   +4 more
doaj   +2 more sources

Three spectrophotometric quantitative analysis of bisoprolol fumarate and telmisartan in fixed-dose combination utilizing ratio spectra manipulation methods [PDF]

Scientific Reports
Hypertension is a chronic condition with multiple drug regimens. Limiting these medicines is critical to patient compliance. Therefore, bisoprolol and telmisartan were recently developed in a fixed-dose combination to control blood pressure.
Osama I. Abdel Sattar, Hamed H. M. Abuseada, Sherif Ramzy, Mahmoud M. Abuelwafa   +3 more
doaj   +2 more sources

Efficacy and Safety of Bisoprolol in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

International Journal of COPD, 2023
Zhouzhou Feng,1 Lu Zhang,1 Yaqin Wang,1 Hong Guo,1 Jian Liu1,2 1The First Clinical Medical College of Lanzhou University, Lanzhou City, People’s Republic of China; 2Gansu Maternal and Child Health Hospital/Gansu Central Hospital, Lanzhou City, People’s ...
Feng Z, Zhang L, Wang Y, Guo H, Liu J
doaj   +2 more sources

Bisoprolol medications in a comparative study on effectiveness and tolerability of original agent and its generic in patients with mild to moderate arterial hypertension

Кардиоваскулярная терапия и профилактика, 2007
Aim. To study clinical equivalence of two bisoprolol medications (Concor ® and Bisogamma®) in patients with mild to moderate arterial hypertension (AH). Material and methods. The study included 32 AH patients (15 men, 17 women): 66 % with Stage I, and 34
S. Yu. Martsevich, S. N. Tolpygina, E. V. Shilova, N. P. Kutishenko, O. V. Lerman, N. A. Dmitrieva, Yu. V. Lukina, V. P. Voronina, A. A. Serazhim   +8 more
doaj   +1 more source

Clinicohemodynamic efficacy of a selective beta-blocker bisoprolol and cytoprotector trimetazidine in the treatment of chronic cardiac failure in patients with ischemic heart disease

Терапевтический архив, 2004
Aim. To assess the effect of a long-term (6 months) treatment with selective beta-blocker bisoprolol, cytoprotector trimetazidine and their combination on the clinical course, left ventricular morphofunctional parameters and quality of life of patients ...
Т A Fedorova, Yu V Ilyina, Т I Sotnikova, M К Rybakova, N V Loschits   +4 more
doaj   +1 more source